+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Ifinatamab Deruxtecan I-DXd compared to the treatment chosen by a physician for people with relapsed small cell lung cancer SCLC. This Phase 3 study aims to see if I-DXd can help participants live longer than current treatments, while also examining other effects such as patient-reported outcomes, immune response, and the drugs behavior in the body. Participants will be randomly assigned to one of two groups. One group will receive I-DXd as an intravenous infusion at a dose of 12 mgkg every 21 days until the disease worsens, unacceptable side effects occur, or other stopping reasons arise. The other group will receive one of the standard treatments chosen by their doctortopotecan, lurbinectedin, or amrubicinaccording to local approved dosing guidelines and until treatment discontinuation criteria are met. During the study, participants will be closely monitored with regular imaging and assessments to track tumor response, disease progression, and quality of life using questionnaires. Safety events and immune responses will also be recorded. Pharmacokinetic samples will be collected at specified times to understand how I-DXd behaves in the body. Participants may remain in the study for up to approximately 3.7 years, allowing for long-term evaluation of outcomes and safety.

Age: 18Years +All GendersPhase 3
229 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Navlimetostat BMS-986504 alone or together with Izalontamab Brengitecan in adults with advanced or metastatic Non-small Cell Lung Cancer NSCLC who have a specific genetic change called homozygous MTAP deletion or MTAP loss. Participants have experienced disease progression despite prior treatments. This is a Phase 2 randomized, open-label trial sponsored by Bristol-Myers Squibb. Participants receive either Navlimetostat alone at one of two doses or in combination with Izalontamab Brengitecan at one of two doses. The study is designed with sequential treatment groups and evaluates these treatments after prior therapies have failed. Dosing details are specified for each drug on designated days, and the study includes assessments to confirm genetic status before treatment. Throughout the study, participants undergo evaluations for tumor response using RECIST criteria, safety monitoring for adverse events including serious reactions up to 28 days after treatment ends, and quality of life assessments related to NSCLC symptoms. The primary outcome focuses on objective tumor response, with follow-up extending up to three years after the last dose. Participants health and laboratory tests are closely monitored during and after treatment to assess safety and efficacy.

Age: 18Years +All GendersPhase 2
67 locations
S

Actively Recruiting

Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.

Age: 18Years +All GendersPhase 3
270 locations
R

Actively Recruiting

This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.

Age: 18Years +All GendersPhase 2Phase 3
321 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination therapy called BMS-986489 Atigotatug plus Nivolumab with Carboplatin and Etoposide compared to Atezolizumab with Carboplatin and Etoposide. This study focuses on participants with extensive-stage small cell lung cancer to understand which treatment works better as a first-line therapy. It is a Phase 3 clinical trial led by Bristol-Myers Squibb. Participants are randomly assigned to one of two groups one receiving the BMS-986489 combination with Carboplatin and Etoposide, and the other receiving Atezolizumab with Carboplatin and Etoposide. All medications are given at specific doses on designated days. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants undergo regular assessments including imaging scans to measure tumor size, and evaluations of overall survival over up to five years. Researchers also monitor symptoms, response duration, progression-free survival, and any adverse or serious side effects up to 135 days after treatment ends. The study includes detailed safety and efficacy tracking with multiple outcome measures to fully understand the impact of each treatment option.

Age: 18Years +All GendersPhase 3
183 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new drug combination, BL-M14D1 with atezolizumab, compared to the current standard treatment in adults with previously untreated extensive-stage small cell lung cancer ES-SCLC. This global, open-label Phase 3 study compares these therapies to standard care, which includes carboplatin plus etoposide chemotherapy and atezolizumab, sometimes followed by lurbinectedin. Participants receive either BL-M14D1 and atezolizumab intravenously every 21 days or the standard treatment consisting of carboplatin, etoposide, and atezolizumab for four cycles, followed by maintenance with atezolizumab alone or with lurbinectedin if approved. Treatments continue based on the protocol, and the study is randomized with parallel groups. During the study, participants undergo regular assessments including scans to measure tumor response, lab tests, and evaluations of safety and quality of life for up to five years. The main outcome is progression-free survival measured for up to two years. Researchers will also monitor overall survival, adverse events, and the impact of treatment on participants well-being over time.

Age: 18Years +All GendersPhase 3
62 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining IPH5201 and durvalumab with standard chemotherapy as a neoadjuvant pre-surgery treatment for patients with resectable early-stage non-small cell lung cancer NSCLC, specifically stages II to IIIA or IIIB with PD-L1 expression of 1% or higher. This phase II, open-label, single-arm multicenter study includes two cohorts, with Cohort 2 currently enrolling patients receiving the combination before surgery. Participants will receive IPH5201, durvalumab, and standard chemotherapy before surgery. In Cohort 1, patients also receive adjuvant treatment with IPH5201 and durvalumab after surgery. The study treatment involves neoadjuvant therapy aimed at improving outcomes before surgery, with Cohort 2 focusing on patients expressing PD-L1 at 1% or more. During the study, participants will be monitored for pathological complete response approximately 16 weeks after the first dose and adverse events up to 90 days after the last dose. Additional assessments include event-free survival, disease-free survival, surgical outcomes, major pathological response, objective response rate, and overall survival up to about two years. Researchers will also study pharmacokinetics and antibody responses during approximately four months of adjuvant treatment, with follow-up visits to assess safety and treatment effects over time.

Age: 18Years +All GendersPhase 2
30 locations
E

Actively Recruiting

Researchers are evaluating Visugromab, an anti GDF-15 antibody, combined with immunochemotherapy in treating adults with newly diagnosed metastatic non-squamous non-small cell lung cancer NSCLC. This Phase 2b randomized, double-blind, placebo-controlled study aims to explore the safety and effectiveness of Visugromab plus standard immunochemotherapy compared to placebo with immunochemotherapy. The trial includes a safety-run-in phase followed by randomized treatment arms to gather preliminary efficacy and safety data.

Age: 18Years +All GendersPhase 2
51 locations